期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

磁性纳米四氧化三铁颗粒对卵巢癌细胞株SKOV3/DDP耐药的逆转作用 被引量：3

原文传递
导出
摘要 目的探讨磁性纳米四氧化三铁颗粒(Fe3O4-MNPs)逆转人卵巢癌顺铂耐药细胞株(SKOV3/DDP)耐药性的机制。方法将SKOV3/DDP细胞分为对照组、顺铂(DDP)组、Fe3O4-MNPs组和DDP+Fe3O4-MNPs组,用Westernblot方法检测P-糖蛋白(P-gp)、肺耐药相关蛋白(LRP)和多耐药相关蛋白1(MRP1),电感耦合等离子体原子发射光谱(ICP)法测定细胞内铂含量。结果 DDP+Fe3O4-MNPs组P-gp、LRP和MRP1蛋白表达水平较DDP组下降明显(P<0.05)。DDP+Fe3O4-MNPs组细胞内铂含量明显高于DDP组(P<0.05)。结论 Fe3O4-MNPs逆转耐药的作用机制可能与Fe3O4-MNPs促进DDP进入细胞内,下调P-gp、LRP和MRP1蛋白表达,提高细胞内DDP浓度有关。
作者 吉金萍 姜智 陈宝安 夏国华
机构地区 南京市浦口区中心医院妇产科 江苏省肿瘤医院妇瘤科 东南大学附属中大医院血液科
出处 《中华临床医师杂志（电子版）》 CAS 2012年第10期196-198,共3页 Chinese Journal of Clinicians(Electronic Edition)
关键词 卵巢肿瘤 抗药性 肿瘤 磁性纳米四氧化三铁颗粒 SKOV3/DDP
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Krishna R, Mayer LD. Multidrug resistance(MDR) in cancer. Mecha- nisms, reversal using modulators of MDR and the role of MDR modula- tors in influencing the Pharmacokinefics of anticancer drug. Eur J Pharm Sci ,2000,11:265-283.
  • 2Omid CF, Cheng J, Benjamin A, et al. Targeted nanoparticle-aptarner bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A ,2006,103:6315-6320.
  • 3Momet S, Vekris A, Bonnet J, et al. DNA-magnetite nonocomposite ma- terials. Mater Leter,2000,42 : 183-188.
  • 4陈洁,吕董,张云甫,张小青,王旋,刘素琴,黄可龙.纳米药物载体Fe_3O_4的可控反应及研究进展[J].材料导报,2006,20(F11):152-154. 被引量：5
  • 5张阳德,肖志刚,张浩伟.载药纳米粒在肝癌靶向治疗中的研究进展[J].中国医学工程,2005,13(6):609-613. 被引量：8
  • 6符淳,李光仪,刘晓英,林秋华,刘风英,谢咏.顺铂诱导卵巢癌耐药细胞系A2780/DDP凋亡的时间和剂量依从性[J].肿瘤防治研究,2006,33(8):561-564. 被引量：9
  • 7栗宝华,胡东晓,赵丽嫣.体外培养人卵巢癌细胞株SKOV-3、SKOV-3/DDP并探讨卵巢癌顺铂耐药机制[J].中国妇幼保健,2005,20(10):1195-1197. 被引量：6
  • 8Liu J, Li C, Qu W, et al. Nitric oxide prodrugs and metallo-chemothera- peutics :JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation. Mol Cancer Ther, 2004, 3: 709-714.
  • 9Troutman MD,Thakker DR. Rhodamine 123 requires carrier-mediatedinflux for its activity as a P-2glycoprotein substrate in Caco-2 cells. Pharm Res,2003,20 : 1192-1199.
  • 10Bergman AM, Pinedo HM, Talianidis I, et aL Increased sensitivity to gemcitabine of P-glycopretein and multi-drug resistance associated protein overexpressing human cancer cell lines. Br Cancer, 2003,88 : 1963-1970.

二级参考文献54

  • 1胡泉涌,郑建华,赵瑾凤.研究C-erbB-2、P53在卵巢上皮性肿瘤中表达及临床意义[J].中国妇产科临床杂志,2003,4(6):445-448. 被引量：1
  • 2Raymond P, Perez T C, Hamilton RF et al. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer, 1993, 71 :1571.
  • 3Brent C Behrens,Thomss C Hamilton,Kidetaka Masuda et al. Characterization of a cis - Diammine Dichloroplatinum (Ⅱ ) resistant human ovarian cancer cell line and its use in evaluation of platinum analoguses. J Biol Chem, 1998, 267:115.
  • 4Vaisman A, Varchenko M, Said Iet al. Cell cycle changes associated with formation of Pt - DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry, 1997, 27:54.
  • 5Beale PJ, Rogers P, Boxall et al. Bcl -2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer, 2000, 82:436.
  • 6Xie K, Fidler I J. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev, 1998, 17:55.
  • 7N Lizuka, K Hirose, T Noma et al. The nm23 - H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesopnageal squamous cell carcinoma. Br J Cancer,1999, 81 : 469.
  • 8Mountz JD, Zhou T, Su X et al. The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune diseases. Clin Immunol Immunopathol, 1996,80:2.
  • 9Scheper RJ,Broxterman H J,Scheffer GL,et al.Overexpression of a Mr 110000 vescular protein in non-p-glucoprotein-mediated multi-drug resistance[J].Cancer Res,1993,53 (7):1475 ～1479.
  • 10Kolfschoten GM,Hulscher TM,Pinedo HM,et al.Drug resistance features and s-phase fraction as possible determinants for drug response in a panel of human ovarian cancer senografes[J].Br J Cancer,2000,83 (7):921 ～ 927.

共引文献30

同被引文献26

  • 1祁萍,安娴,高丽萍,魏虎来.siRNA逆转白血病K562/ADM细胞对抗癌药物耐受性的研究[J].中华肿瘤防治杂志,2008,15(9):648-651. 被引量：5
  • 2Lara PC,Pruschy M,Zimmermann M, et al. MVP and vauhs:a role in the radiation response[ J]. Radiat Oncol,2011,6 : 148.
  • 3Chen ZJ, Le BH, Zhang YK, et al. Lung resistance protein and multidrug resistance in non-small cell and their clinical signifi- cance[ J ]. The Journal of International Medical Research, 2011, 39 : 1693 - 1700.
  • 4Huang WT, Huang CC, W eng SW,et al. Expression of the multi- drug resistance protein MRP and the lungresistance protein LRP in nasal NK/T cell lymphoma:further exploring the role of p53 and W T1 gene[ J] . Pathology,2009,41 (2) :127 - 132.
  • 5De Moraes ACR,Maranho CK,Rauber GS. Improtance of detecting multidrug resistance proteins in acute Leukemia prognosis and therapy [ J ]. Journal of clinical laboratory analysis, 2013,27 : 62 - 71.
  • 6Hideaki TANAKA, Tomitake TSUKIHARA. Structural studies of large nucleoprotein particles, vaults[ J ]. Proc Jpn Acad Ser B Phy Biol Sci ,2012,88 (8) :416 - 33.
  • 7Min Han, Qing Lv, Jian-Qing Gao, et al. Overcoming drug resist- ance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA poly- amidoamine-hyaluronic acid complex [ J ]. Journal of Controlled Release,163 (2012) :136 - 144.
  • 8Daly TK, Sutherland-Srnith A J, Penny D. In silico resurrection of the major vault protein suggests it is ancestral in modem eukaryotes [J]. Genome Biol Evol,2013,5(8) :1567 - 1583.
  • 9Room LH, Kickhoefer VA. Development of the Vault Particle as a Platform Technology[ J]. ACS Nano ,2013,7 (2) :889 - 902.
  • 10Buehler DC,Toso DB, Kickhoefer VA. Vaults engineered for hydro- phobic drug delivery[ J]. Small ,2011,7 ( 10 ) : 1432 - 9.

引证文献3

中华临床医师杂志（电子版）
2012年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部